Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Background Therapy, Lyr-210, Sham Procedure Control
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Phase III
Completed
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
Mar 08, 2022
―
Background Therapy, Lyr-210, Sham Procedure Control
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Phase III
Completed
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Jan 21, 2022
―
Lyr-220 Design 1 (Part 1 Only), Lyr-220 Design 2 (Part 1 And Part 2), Bilateral Sham Procedure Control (Part 2)
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Phase II
Completed
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
Aug 27, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lyra Therapeutics (LYRA) have in its pipeline
LYRA is currently developing the following drugs: Background Therapy, Lyr-210, Sham Procedure Control, Background Therapy, Lyr-210, Sham Procedure Control, Lyr-220 Design 1 (Part 1 Only), Lyr-220 Design 2 (Part 1 And Part 2), Bilateral Sham Procedure Control (Part 2). These drug candidates are in various stages of clinical development as the company works toward FDA approval.